Overview of the MINDACT trial results presented at EBCC-12
Published: 16 Oct 2020
Views: 339
Prof Etienne Brain - EORTC Breast cancer group chair
Prof Etienne Brain discusses with ecancer the results of the MINDACT trial presented at EBCC-12.
He talks about the importance of this trial and why it was initiated in the first place and how the long term follow-up has proved successful in using certain drug combinations for chemotherapy against breast cancer.
He says age is also a factor that impacts the type and prognosis of chemotherapy used.
Related Videos
Survival analysis of newly diagnosed transplant-eligible multiple myeloma patien...
Dr Francesca Gay - University of Torino, Torino, Italy
14 Dec 2020
Highlights from EBCC-12
Prof Nadia Harbeck - EBCC Conference Chair
23 Oct 2020
Breast cancer roundup from ESMO 2020
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
23 Sep 2020
OncoAlert and ecancer weekly roundup for September 6-13, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
14 Sep 2020
Update from KAITLIN for high-risk HER2-positive early breast cancer
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
29 May 2020
Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associate...
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
29 May 2020
PARP inhibitors for metastatic breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
7 Oct 2019
Melanoma highlights from ESMO 2019
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
30 Sep 2019
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019
Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith
30 Sep 2019
